Plasminogen activators and matrix metalloproteinases in angiogenesis

Enzyme and Protein

Volumn 49, Issue 1-3, 1996, Pages 117-137

  Mignatti, Paolo ^a   Rifkin, Daniel B ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

Angiogenesis; Metalloproteinases; Plasminogen activators

Indexed keywords

METALLOPROTEINASE; PLASMIN; PLASMINOGEN ACTIVATOR; UROKINASE;

ANGIOGENESIS; BASEMENT MEMBRANE; CAPILLARY; CELL DEGENERATION; CELL MIGRATION; CELL PROLIFERATION; EXTRACELLULAR MATRIX; HUMAN; PROTEIN DEGRADATION; REVIEW; TRANSCRIPTION REGULATION; VASCULAR ENDOTHELIUM;

EID: 0029943568     PISSN: 10196773     EISSN: None     Source Type: Journal    
DOI: 10.1159/000468621     Document Type: Review

References (216)

1. Mignatti P. Rifldn DB: Biology and biochemistry of proteina.ses in tumor invasion. Physiol Rev 1993:73: 161-195.
2. Moscateili D. Rifkin DB: Membrane and matrix localization of proteinases: A common theme in tumor cell invasion and angiogenesis. Biochim Biophys Acta 1988:948:67-85.
3. Kleiner DE. Stetler-Stevenson WG: Structural biochemistry and activation of matrix metalloproteinases. Curr Opin Cell Biol 1993:5:891-897.
4. Malrisian LM: Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990:6:121-125.
5. Murphy G. Allan JA. Willenbrook F. Cockett MI. Q'Connell JP. Docherty AJP: The C terminal domain in collagenase and stromelysin specificity. J Biol Chem 1992:267:9612-9618.
6. Werb Z. Mainardi C. Vater CA, Harris ED: Endogenous activation of latent collagenase by rheumatoid syn ovial cells. Evidence fora role of plasminogen activator. N Engl J Med 1977:296:1017-1023.
7. Werb Z. Banda MJ. Jones PA: Degradation of connective tissue matrices by macrophases. I. Proteolysis of elastin, glycoproteins and collagen by proteinases isolated from macrophages. J Exp Med 1980:152: 1340-1357.
8. Chapman HA. Stone OL Jr: Cooperation between plasmin and elastase in elastin degradation by intact mu rine macrophages. Biochem J 1984:222:721-728.
9. Hasty KA. Pourmotabbed TF, Goldberg GI. Thompson JP, Spinella DG. Stevens RM. Mainardi CL: Human neutrophil collagenase. A distinct gene product with homology to other matrix metalloproteinases. J Biol Chem 1990:265:11421-11424.
10. Freije JMP, Diez-Itza 1. Balbin M. Sanchez LM. Blasco R. Tolivia J. Lopez-Otin C: Molecular cloning and expression of collagenase-3. a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 1994:269:16766-16773.
11. Quinn CO, Scott DK, Brinckerhoff CE. Matrisian LM, Jeffrey JJ, Partridge NC: Rat collagenase: Cloning, amino acid sequence comparison and parathyroid hormone regulation in osleoblastic cells. J Biol Chem 1990:265:13521-13527.
12. Chin JR, Murphy G. Werb Z: Stromelysin. a connective tissue-degrading metalloendopeptidase secreted by stimulated rabbit synovial fibroblasts in parallel with collagenase. J Biol Chem 1985:260:12367-12376.
13. Goldberg GI. Wilhelm SM. Kronberger A, Bauer EA. Grant GA, Eisen AZ: Human fibroblast collagenase. Complete primary structure and homology to an oncogene transformation-induced rat protein. J Biol Chem 1986:261:6600-6605.
14. Nicholson R, Murphy G. Breathnach R: Human and rat malignant-tumor-associated mRNAs encode stromelysm-like metalloproteinases. Biochemistry 1989:28:5195-5203.
15. Quantin B, Murphy G, Breathnach R: Pump-1 cDNA codes for a protein with characteristics similar to those of classical collagenase family members. Biochemistry 1989;28:5327-5334.
16. Sanchez-Lopez R, Nicholson R, Gesnel M-C, Matrisian LM, Breathnach R: Structure-function relationships in the collagenase family member transin. J Biol Chem 1988:263:11892-11899.
17. Wilhelm SM, Collier IE, Kronberger A, Eisen AZ, Manner BL, Grant GA, Bauer EA, Goldberg GI: Human skin fibroblast stromelysin: Structure, glycosylation, substrate specificity, and differential expression in normal and tumorgenic cells. Proc Natl Acad Sei USA 1987;84:6725-6729.
18. Wilhelm SM, Collier IE, Marmer BL, Eisen AZ, Grant GA, Goldberg GI: SV40-transformed human lung fibroblasts secrete a 92-kD type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 1989:264:17213-17221.
19. Woessner JF Jr, Taplin CJ: Purification and properties of a small latent matrix metalloproteinase of rat uterus. i Biol Chem 1988:263:16918-16925.
20. Basset P, Belloq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajcer ÖL, Chenard MP, Rio MC, Chambon P: A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990:348: 699-704.
21. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 1994;370:61-65.
22. Cao J, Sato H, Takino T, Selki M. The C-terminal region of membrane-type matrix metalloproteinase is a functional transmembrane domain required for pro-gelatinase A activation. J Biol Chem 1995:270:801-805.
23. Shapiro SD, Griffin GL, Gilber DJ, Jenkins NA, Copeland NG, Welgus HG, Senior RM, Ley TJ: Molecular cloning, chromosomal localization and bacterial expression of a novel murine macrophage metalloelastase. J Biol Chem 1992:267:46641671.
24. Shapiro SD, Kobayashi D, Pentland AP, Welgus HG: Induction of macrophage metalloproteinases by extracellular matrix substrates: Evidence for enzyme- and substrate-specific responses involving prostaglandin-dependent mechanisms. J Biol Chem 1993:268:8170-8175.
25. Miller EJ, Harris ED Jr, Chung E, Finch FE Jr, McCroskery PA, Butler WT: Cleavage of type II and III collagens with mammalian collagenase: Site of cleavage and primary structure of the NH2-terminal portion of the smaller fragment released from both collagens. Biochemistry 1976;15:787-792.
26. Schmid TM, Mayne R, Jeffery JJ, Lisenmayer TF: Type X collagen contains two cleavage sites for a vertebrate collagenase. J Biol Chem 1986:261:4184-189.
27. Collier IE, Wilhelm SM, Eisen AZ, Marmer BL, Grant GA, Seltzer JL, Kronberger A, He C, Bauer EA. Goldberg GI: H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloproteinase capable of degrading basement membrane collagen. J Biol Chem 1988:263:6579-6587.
28. Liotta LA, Abe S, Robey PG, Martin GR: Preferential digestion of basement membrane collagen by an enzyme derived from a metastatic murine tumor. Proc Natl Acad Sei USA 1979:5:2268-2272.
29. Seltzer JL, Eisen AZ, Bauer EA, Morris NP, Glanville RW, Burgeson RE: Cleavage of type VII collagen by interstitial collagenase and type IV collagenase (gelatinase) derived from human skin. J Biol Chem 1989;264: 3822-3826.
30. Welgus HG, Fliszar CJ, Seltzer JL, Schmid TM, Jeffrey JJ: Differential susceptibility of type X collagen to cleavage by two mammalian Interstitial collagenases and 72-kD type IV collagenase. J Biol Chem 1990; 265:13521-13527.
31. Aimes RT, Quigley JP: Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4length fragments. J Biol Chem 1995;270:5872-5876.
32. Murphy G, Segain JP, O'Shea M, Cockett M, loannou O, Lefebvre O, Chambon P, Basset P: The 28-kD N-terminal domain of mouse stromelysin-3 has the general properties of a weak metalloproteinase. J Biol Chem 1993:268:15435-15441.
33. Herron GS, Banda MJ, Clark EJ, Gavrilovic J, Werb Z: Secretion of metalloproteinase by stimulated ccpillary endothelial cells. II. Expression of collagenase and stromelysin activitries is regulated by endogenous inhibitors. J Biol Chem 1986:261:2814-2818.
34. Okada Y, Nagase H, Harris ED: A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization. J Biol Chem 1986:261:14245-14255.
35. Werb Z: Proteinases and matrix degradation; in Kelley WN, Harris ED, Ruddy S, Sledge CB (eds.): Textbook of Rheumatology ed 3. Philadelphia, Saunders, 1989; pp 300-321.
36. Murphy G, Cockett MI, Ward RV, Docherty AJP: Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kD and 75 kD gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase, Biochem J 1991;277:277-279.
37. Sires UI, Griffin GL, Broekelmann TJ, Mecham RP, Murphy G, Chung AE, Welgus HG, Senior RM: Degradation of entactin by matrix metalloproteinases. Susceptibility to matrilysin and identification of cleavage sites. J Biol Chem 1983;268:2069-2074.
38. Rodgers WH, Osteen KG, Matrisian LM, Navre M, Giudice LC, Gorstein F: Expression and localization of matrilysin, a matrix metalloproteinase, in human endometrium during the reproductive cycle. Am J Obstet Gynecol 1993:168:253-280.
39. Kerr LD, Holt JT, Matrisian LM: Growth factors regulate transin gene expression by c-/os-dependent and c/os-independent pathways. Science 1988;242:1424-1427.
40. Kerr LD, Miller D, Matrisian LM: TGF-βi inhibition of transin/stromelysin gene expression is mediated through a/os binding sequence. Cell 1990;61.-267-278.
41. Masure S, Billiau A, Van Damme J, Opdenakker G: Human hepatoma cells produce an 85 kD gelatinase regulated by phorbol-12-myristate acetate. Biochim Biophys Acta 1990:1054:317-325.
42. Salo T, Turpeenniemi-Hujanen T, Tryggvason K: Tumor-promoting phorbol esters and cell proliferation stimulate secretion of basement membrane (type IV) collagen-degrading metalloproteinase by human fibroblasts. J Biol Chem 1985:260:8526-8531.
43. Schönthal A, Herrlich P, Rahmsdorf HJ. Ponta H: Requirement for/< gene expression in the transcriptional activation of collagenase by other oncogenes and phorbol esters. Cell 1988:54:325-334.
44. Buttice G. Quinones S. Kurkinen M: The AP-1 site is required for basal expression but is not necessary for TPA-response of the human stromelysin gene. Nucleic Acids Res 1991:19:3723-3731.
45. Buttice G, Kurkinen M: A polyomavirus enhancer A-binding protein-3 site and Ets preotein have a major role in the 12-O-tetradecanoylphorbol-13-acetate response of the human stromelysin gene. J Biol Chem 1993: 268:7196-7204.
46. Gaire M. Magbanus Z. McDonnell S. McNeil L, Lovett DH. Matrisian LM: Structure and expression of the human gene for the matrix metalloproteinase matrilysin. J Biol Chem 1994:269:2032-2040.
47. Vincenti MP, Coon CI. Brinckerhoff CE: Regulation of collagenase gene expression by IL-1-heta requires transcriptional and post-transcriptional mechanisms. Nucleic Acids Res 1994:22:4818-4827.
48. Curran T. Franza BR Jr: Fos and jun: The AP-1 connection. Cell 1988:55:395-397.
49. Sudbeck BD, Parks WC, Welgus HG, Pentland AP: Collagen-stimulated induction of keratinocyte collagenase is mediated via tyrosine kinase and protein kinase C activities. J Biol Chem 1994:269:30022-30029.
50. 5(1 Frisch SM, Clak EJ; Werb Z: Coordinate expression of stromelysin and collagenase genes determined with cDNA probes. Proc Nail Acad Sei USA 1987:84:2600-2604.
51. He C, Wilhelm MW. Pentland AP. Marmer BL. Grant G A. Eisen AZ. Goldberg GI: Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sei USA 1989:86:2632-2636.
52. Desrivieres D. Lu H. Peyri N, Soria C, Legrand Y. Menashi S: Activation of the 92 kD Type IV collagenase by tissue kallikrein. J Cell Physiol 1993:157:587-593.
53. Watanabe H. Nakanishi I, Yamashita K. Hayakawa T, Okada YP: Matrix metalloproteinase-9 (92 kD gelatinase/type IV collagenase) from U937 monoblastoid cells: Correlation with cellular invasion. J Cell Sei 1993: 104:991-999.
54. Okada Y, Gonoji Y, Naka K, Tomita K. Nakanishi I. Iwata K, Yamashita K. Hayakawa T: Matrix metalloproteinase 9 (92-kD gelatinase/type IV collagenase) from HT1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J Biol Chem 1992:267:21712-21719.
55. Hanemaaijer R. Koolwijk P, le Clercq L, de Vree WJ. van Hinsberg VW: Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumor necrosis factor-alpha. interleukin-1 and phorbol ester. Biochem J 1993:296:803-809.
56. Campbell EJ. Cury JD, Lazarus CJ, Welgus HG: Monocyte procollagenase and tissue inhibitor of metalloproteinases. Identification, characterization, and regulation of secretion. J Biol Chem 1987:262:15862-15868.
57. Stricklin GP. Eisen AZ. Bauer EA. Jeffrey JJ: A specific inhibitor of vertebrate collagenase: Chemical proper ties of precursor and active forms. Biochemistry 1978:17:2331-2335.
58. Stricklin GP. Welgus HG: Human skin fibroblast collagenase inhibitor. Purification and biochemical characterization. J Biol Chem 1983:258:12252-12258.
59. Welgus HG, Stricklin GP: Human skin fibroblast collagenase inhibitor: Comparative studies in human connective tissues, serum, and amniotic fluid. J Biol Chem 1983:258:12259-12264.
60. Welgus HG, Stricklin GP, Eisen AZ, Bauer EA, Cooney RV. Jeffrey JJ: A specific inhibitor of vertebrate col lagenase produced by human skin fibroplasts. J Biol Chem 1979:254:1938-1943.
61. Stetler-Stevenson WG, Krutsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP 2). A new member of the metalloproteinase inhibitor family. J Biol Chem 1989:264:17374-17378.
62. Stetler-Stevenson WG. Brown PD. Onisto M. Levy AT, Liotta LA: Tissue inhibitor of metaIloproteinases-2 (T1MP-2) mRNA expression in tumor cell lines and human tumor tissues. J Biol Chem 1990:265:13933-13938.
63. Leco KJ. Khokha R. Pavloff N. Hawkes SP. Edwards DR: TIMP-3 is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Bio] Chem 1994:289:9352-9360.
64. Baragi V. Fliszar CJ. Conroy MC. Ye Q-Z, Shipley JM. Welgus HG: Contribution of the C-terminal domain of metalloproteinases to binding by TIMP: C-terminal truncated stromelysin and matrilysin exhibit equally compromised affinities as compared to full-length stromelysin. J Biol Chem 1994:269:12692-12697.
65. Murphy G, Allan JA, Willenbrock F. Cockett MI, O'Connell JP. Docherty AJP: The C-terminal domain in col lagenase and stromelysin specificity. J Biol Chem 1992:267:9612-9618.
66. Goldberg GI. Marmer BI. Grant GA, Eisen AZ. Wilhelm S. He C: Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP 2. Proc Natl Sei USA 1989:86: 8207-8211.
67. Murphy G. Willenbrock F, Ward RV. Cockett MI, Eaton D, Docherty AJP: The C-terminal domain of 72 kD gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. Biochem J 1992:283:637-641.
68. Ward RV, Atkinson SJ. Slocombe PM, Docherty AJ, Reynolds JJ, Murphy G: Tissue inhibitor of metalloproteinases 2 inhibits the activation of 72 kD progelatinbase by fibroblast membranes. Biochim Biophys Acta 1991:1079:242-246.
69. Goldberg GI, Strongin A, Collier IE, Genrich LT, Marmer BL: Interaction of 92-kD type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 1992;267:4583-4591.
70. Itoh Y, Binner S, Nagase H: Steps involved in activation of the complexes of pro-matrix metalloproteinase 2 (progelatinase A) and tissue inhibitor of metalloproteinases (TlMP)-2 by 4-aminochenylmercuric acetate. BiochemJ 1995:308:645-651.
71. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI: Mechanism of cell surface activation of 72-kD, type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995:270:5331-5338.
72. Edwards DL. Murphy G, Reynolds JJ, Whitham SA, Docherty AJP, Angel P. Heath JK: Transforming growth factor-beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987:6: 1899-1904.
73. Pepper MS, Belin D, Montesano R. Orci L, Vassalli J-D: Transforming growth factor-beta-1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol 1990:111:743-755.
74. Saksela O, Moscatelli D. Rifkin DB: The opposing effects of basic fibroblasts growth factor and transforming growth factor-beta on the regulation of plasminogen activator activity in capillary endothelial cells. J Cell Biol 1987:105:957-963.
75. Moscatelli D, Presta M, Rifkin DB: Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis and migration. Proc Natl Acad Sei USA 1986:83:2091-2095.
76. Rifkin DB, Moscatelli D: Recent developments in the cell biology of basic fibroblast growth factor. J Cell Biol 1989:109:1-6.
77. Robbins KC, Summaria L: Human plasminogen and plasmin. Methods Enzymol 1970:19:184-199.
78. Isseroff RR, Rifkin DB: Plasminogen is present in the basal layer of epidermis. J Invest Dermatol 1983; 80:297-299.
79. Chapman HA, Stone OL Jr: Cooperation between plasmin and elastase in elastin degradation by intact murine macrophages. Biochem J 1984:222:721-728.
80. Werb Z, Mainardi C, Vater CA. Harris ED: Endogenous activation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N Engl J Med 1977:296:1017-1023.
81. Kristensen P, Larsson LI, Nielsen LS. Gr0ndahl-Hansen J, Andreasen PA, Dan0 K: Human endothelial cells contain one type of plasminogen activator. FEBS Lett 1984:168:33-37.
82. Laug WE, Tokes ZA, Benedict WE, Sorgente N: Anchorage independent growth and plasminogen activator production by bovine endothelial cells. J Cell Biol 1980:84:281-293.
83. Bykowska K, Levin EG, Rijken DC. Loskutoff DJ, Collen D: Characterization of a plasminogen activator secreted by cultred bovine aortic endothelial cells. Biochim Biophys Acta 1982:703:113-115.
84. Levin EG, Loskutoff DJ: Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators. J Cell Biol 1982:94:631-636.
85. Philips M, Juul AG, Thorsen S: Human endothelial cells produce a plasminogen activator inhibitor and a tissue plasminogen activator-inhibitor complex. Biochim Biophys Acts 1984:802:99-110.
86. Tsuboi R. Sato Y. Rifkin DB: Correlation of cell migration, cell invasion, receptor number, proteinase production, and basic fibroblast growth factor levels in endothelial cells. J Cell Biol 1990:110:511-517.
87. Peverali FA, Mandriota S, Ciana P, Marelli R, Quax P. Rifkin DB, Delia Valle G, Mignatti P: Tumor cells secrete an angiogenic factor that stimulates basic fibroblast growth factor and urokinase expression in vascular endothelial cells. J Cell Physiol 1994:161:1-14.
88. Bacharach E, Hin A, Keshet E: In vivo patterns of expression of urokinase and its inhibitor PA1-1 suggest a concerted role in regulating physiological angiogenesis. Proc Natl Acad Sei USA 1992:89:10686-10690.
89. Loskutoff DJ, Edgington TB: Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sei USA 1977:74:3903-3907.
90. Hekman CM, Loskutoff DJ: Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by dénaturants. J Biol Chem 1985:260:11581-11587.
91. Kawano T, Morimoto K, Uemura Y: Partial purification and properties of urokinase inhibitor from human placenta. J Biochem 1970:67:333-342.
92. Astedt B, Lecander I, Brodin T, Ludblad A, Low K: Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator. Thromb Haemost 1985:53:122-125.
93. Kruithof EKO, Vassalli JD, Schleuning W-D, Mattaliano RJ, Bachmann F, Purifikation and characterization of a plasminogen activator inhibitor from the histocytic lymphoma cell line U-937. J Biol Chem 1986;261: 11207-11213.
94. Baker JB, Low DA, Simmer RL, Cunningham DD: Protease-nexin: A cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell 1980;21:37-45.
95. Eaton DL, Scott RW, Baker JB: Purification of human fibroblast urokinase proenzyme and analysis of its regulation by proteases and protease nexin. J Biol Chem 1984:259:6241-6247.
96. Heeb MJ, Espana F, Geiger M, Collen D, Stump DC, Grifin JH: Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor-3. J Biol Chem 1987:262: 15813-15816.
97. Barnathan ES, Kup A, Kariko K, Rosenfeld L, Murray SC, Behrendt N, R0nne E, Weiner D, Henkin J, Cines DB: Characterization of human endothelial cell urokinase-type plasminogen activator receptor protein and messenger RNA. Blood 1990:76:1795-1806.
98. Barnathan ES, Kuo A, Rosenfeld L, Kariko K, Leski M, Robbiati F, Nolli ML, Henkin J,. Cines DB: Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells. J Biol Chem 1990; 265:2865-2872.
99. Behrendt N, R0nne E, Ploug M, Pétri T, L0ber D, Nielsen LS, Schleuning W-D, Blasi F, Appella E, Dane K: The human receptor for urokinase plasminogen activator. NHi-terminal sequence and glycosylation variants. J Biol Chem 1990:265:6453-6460.
100. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dan0 K, Appella B, Blasi F: Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 1990;9:467-474.
101. Mignatti P, Mazzieri R, Rifkin DB: Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor. J Cell Biol 1991;! 13:1193-1201.
102. Ploug M, R0nne E, Behrendt N, Jensen AL, Blasi F, Dan0 K: Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosylphosphatidylinositol. J Biol Chem 1991:266:1926-1933.
103. M0ller LB, Pöllanen J, R0nne E, Pedersen N, Blasi F: N-linked glycosylation of the ligand-binding domain of the human urokinase receptor contributes to the affinity for its ligand. J Biol Chem 1993:268:11152-11159.
104. Mandriota S, Seghezzi G, Vassalli JD, Ferrara N, Wasi S. Mazzieri R, Mignatti P, Pepper MS: Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 1995: 270:9709-9716.
105. Appella E, Robinson EA, Ullrich SJ, Stoppelli MP, Corti A. Cassani G, Blasi F: The receptor-binding sequence of urokinase. A biological function for the growth factor module of proteases. J Biol Chem 1987:262: 4437-4440.
106. Vassalli J-D, Baccino D, Belin D: A cellular binding site for the M, 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 1985:100:86-92.
107. Hebert CA. Baker JB: Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: Colocalization of cell surface urokinase with vinculin. J Cell Biol 1988:106:1241-1248.
108. Pöllanen J, Hedman K, Nielsen LN, Dan0 K. Vaheri A: Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol 1988:106:87-95.
109. Ellis V. Behrendt N, Dan0 K: Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 1991:266:12752-12758.
110. Lee SW, Ellis V, Dichek DA: Characterization of piasminogen activation by glycosylphosphatidylinositol-anchored urokinase. J Biol Chem 1994:259:2411-2418.
111. Cubellis MV, Wun TC, Blasi F: Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 1990:9:1079-1085.
112. Hajjar KA, Hamel NM: Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase. J Biol Chem 1990:265:2908-2916.
113. Felez J, Chanquia CJ, Fabregas P, Plow EF, Miles LA: Competition between plasminogen and tissue plasminogen activator for cellular binding sites. Blood 1993:82:2433-2441.
114. Hajjar KA: The endothelial cell tissue plasminogen activator receptor. Specific interaction with plasminogen. J Biol Chem 1991:266:21962-21970.
115. Hajjar KA: Homocysteine-induced modulation of tissue plasminogen activator binding to its endolhelial cell membrane receptor. J Clin Invest 1993:91:2873-2879.
116. Hajjar KA. Jacovina AT, Chacko J: An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. identity with annexin II. J Biol Chem 1994:269:21191-21197.
117. Cesarman GM, Guevara CA. Hajjar KA: An endothelial cell receptor for plasminogen/tissue plasminogen activator (I-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem 1994:269:21198-21203.
118. Ramakrishnan V, Sinicropi DV, Dere R, Darbonne WC. Bechtol KB, Baker JB: Interaction of wild-type and catalytically inactive mutant forms of tissue-type plasminogen activator with human umbilical vein endothelial cell monolayers. J Biol Chem 1990:265:2755-2762.
119. Rüssel NE, Quertermous T, Declerck PJ, Collen D, Haber E. Homey CJ: Binding of tissue-type plasminogen activator with human endothelial cell monolayers. Characerization of the high affinif y interaction with plasminogen activator inhibitor-1. J Biol Chem 1990:265:2569-2575.
120. Wittwer AJ. Sanzo MA: Effect of peptides on the inactivation of tissue plasminogen activator by plasminogen activator inhibitor-1 and on the binding of tissue plasminogen activalor to endothelial cells. Thromb Haemost 1990:64:270-275.
121. Morton PA, Owensby DA. Wun TC, Billadello J, Schwartz AL: Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells. J Biol Chem 1990:265:14093-14099.
122. Shih GC, Hajjar KA: Plasminogen and plasminogen activator assembly on the human endothelial cell. Proc Soc Exp Biol Med 1993;202:258-264.
123. Kanalas JJ, Makker SP: Identification of the rat Heymann nephritis autoantigen (gp330) as a receptor site for plasminogen. J Biol Chem 1991:266:10825-10829.
124. Miles LA, Dahlberg CM, Plescia J, Fêlez J, Kalo K, Plow EF: Role of cell-surface lysines in plasminogen binding to cells: Identification of alpha-enolase as a candidate plasminogen receptor. Biochemistry 1991 ;30: 1682-1691.
125. Miles LA, Plow EF: Binding and activation of plasminogen on the platelet surface. J Biol Chem 1985;260: 4303-4311.
126. Hajjar KA, Harpel PC, Jaffe EA, Nachman RL: Binding of plasminogen to cultured human endothelial cells. J Biol Chem 1966;261:11656-11662.
127. Plow EF, Freaney DE, Plescia J, Miles LA: The plasminogen system and cell surfaces: Evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 1986;103:2411-2420.
128. Plow EF, Miles LA: Plasminogen receptors in the mediation of pericellular proteolysis. Cell Differ Dev 1990; 32:293-298.
129. Andrade-Gordon P, Strickland S: Interaction of heparin with plasminogen activators and plasminogen: Effects on the activation of plasminogen. Biochemistry 1986:25:4033-4040.
130. Moser TL, Enghild JJ, Pizzo SV, Stack MS: The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator. J Biol Chem 1993;268: 18917-18923.
131. Eisenstein R, Sorgente N, Sohle LW, Miller A, Kuettner KE: The resistance of certain tissues to invasion: Penetrability of explanted tissues by vascularized mesenchyme. Am J Pathol 1973;73:765-774.
132. Eisenstein R, Kuettner KE, Neapolitan C, Soble LW, Sorgente N: The resistance of certain tissues to invasion. III. Cartilage extracts inhibit the growth of fibroblasts and endothelial cells in culture. Am J Pathol 1975; 81:337-347.
133. Sorgente N, Kuethner KE, Soble LW, Eisenstein R: The resistance of certain tissues to invasion. II. Evidence for extractable factors in cartilage which inhibit invasion by vascularized mesenchyme. Lab Invest 1975;32: 217-222.
134. Brem H, Folkman J: Inhibition of tumor angiogenesis mediated by cartilage. J Exp Med 1975;141:427-439.
135. Langer R, Brem H, Falterman K, Klein M, Folkman J: Isolations of a cartilage factor that inhibits tumor necovascularization. Science 1976;193:70-72.
136. Langer R, Conn H, Vacant! J, Haudenschild C, Folkman J: Control of tumor growth in animals by infusion of an angiogenesis inhibitor. Proc Natl Acad Sei USA 1980;77:4331t335.
137. Moses MA, Langer R: A metalloproteinase inhibitor as an inhibitor of neovascularization (review). J Cell Biochem 1991;47:230-235.
138. Murray JB, Allison K, Sudhalter J, Langer R: Purification and partial amino acid sequence of a bovine cartilage-derived collagenase inhibitor. J Biol Chem 1986;261:4154-4159.
139. Johnson MD, Kim HR, Chester L, Tsao-Wu G, Bouck N, Polverini PJ: inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 1994:160:194-202.
140. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980;284:67-68.
141. Moscatelli D, Jaffe E, Rifkin DB: Tetradecanoyl phorbol acetate stimulates latent collagenase production by cultured human endothelial cells. Cell 1980;20:343-351.
142. Gross JL, Moscatelli D, Rifkin DB: Increased capillary endothelial cell protease activity in response to angiogenic stimuli in vitro. Proc Natl Acad Sei USA 1983;80:2623-2627.
143. Montesano R, Orel L: Tumor-promoting phorbol esters induce angiogenesis in vitro. Cell 1985:42:469-477.
144. Montesano R, Vassalli JD, Baird A, Guillemin R, Orci L: Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sei USA 1986:83:7297-7301.
145. Montesano R, Pepper MS, Vassalli JD, Orci L: Phorbol ester induces cultured endothelial cells to invade a fibrin matrix in the presence of fibrinolytic inhibitors, i Cell Physiol 1987;132:509-516.
146. Montesano R, Pepper MS, Belin D, Vassalli JD, Orci L: Induction of angiogenesis in vitro by vanadate, an inhibitor of phosphotyrosine phosphatases. J Cell Physiol 1988;134:460-466.
147. Laterra J, Indurti RR, Goldstein GW: Regulation of in vitro glia-induced microvessel morphogenesis by urokinase. J Cell Physiol 1994;! 58:317-324.
148. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, Fauci AS: Transforming growth factor type β: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sei USA 1986:83:4167-4171.
149. Yang EY, Moses HL: Transforming growth factor-βj-induced changes in cell migration, proliferation, and angiogenesis in the chick chorioallantoic membrane. J Cell Biol 1990;111:731-741.
150. Ferrara N, Houck KA, Jakerman LB, Winer J, Leung DW: The vascular endothelial cell growth factor family of polypeptides. J Cell Biochem 1991:47:211-218.
151. Pepper MS, Ferrara N, Orci L. Montesano R: Vascular endothelial cell growth factor induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991;181:902-906.
152. Basilico C, Moscatelli D: The FGF family of growth factors and oncogenes. Adv Cancer Res 1992;59:115-165.
153. Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickoloff BJ, Kinsella JL, Polverini P, Rosen EM: Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sei USA 1993;90:1937-1941.
154. Pepper MS, Ferrara N, Orci L, Montesano R: Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992:189:824-831.
155. Mizuno K, Nakamura T: Molecular characteristics of HGF and the gene, and its biochemical aspects. Experientia 1993;65:l-29.
156. Naldini L, Tamagnone L, Vigna E, Sachs M, Hartmann G, Birchmeier W, Daikuhara Y, Tsubouchi H, Blasi F, Comoglio PM: Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBOJ 1992;! 1:4825(833.
157. Pepper MS. Matsumoto K, Nakamura T, Orci L, Montesano R: Hepatocyte growth factor increases urokinase-type plasminogen activator (u-PA) and u-PA receptor expression in Madin-Darby canine kidney epithelial cells. J Biol Chem 1992:267:20493-20496.
158. Bussolino F, Di Renzo MF, Ziehe M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A. Comoglio PM: Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992:119:629-641.
159. Thompson EA. Nelles L, Collen D: Effect of retinoic acid on the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in human endothelial cells. Eur J Biochem 1991:201:627-632.
160. Van Hinsbergh VW, van den Berg EA, Fiers W, Dooijewaard G: Tumor necrosis
161. Mignatti P, Tsuboi R, Robbins E. Rifkin DB: in vitro angiogenesis on the human amniotic membrane: Requirement for basic fibroblast growth factor-induced proteinases. J Cell Biol 1989:108:671-682.
162. Saksela O, Rifkin DB: Cell-associated plasminogen activation: Regulation and physiological functions. Annu Rev Cell Biol 1988:4:93-126.
163. Montesano R, Pepper MS, Möhle-Steinlein U. Risau W. Wagner EF. Orci L: Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 1990:62:435145.
164. Dubois-Stringfellow N, Jonczyk A, Bautch VL: Perturbations in the fibrinolytic pathway abolish cyst formation but not capillary-like organization of cultured murine endothelial cells. Blood 1994:83:3206-3217.
165. Carmeliet P, Schoonjans L, Kieckens L. Ream B. Degen J, Bronson R, De Vos R. van den Oord JJ, Collen D. Mulligan RC: Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994: 386:419-425.
166. Blei F. Wilson EL. Mignatti P, Rifkin DB: Mechanism of action of angiostatic steroids: Suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol 1993;155: 568-578.
167. Wolff JE. Guerin C, Laterra J. Bressler J, Indurti RR, Brem H. Goldstein GW: Dexamethasone reduces vascular density and plasminogen activator activity in 9L rat brain tumors. Brain Res 1993:604:79-85.
168. Folkman J: How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award Lecture. Cancer Res 1986:46:467-473.
169. Folkman J: What is the evidence that tumors are angiogenesis dependent? (editorial) J NatI Cancer Inst 1990; 82:4-6.
170. Folkmann J. Watson K, Ingber D, Hanahan D: Induction of angiogenesis during the translition from hyperplasia to neoplasia. Nature 1989:339:58-61.
171. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma. N Engl J Med 1991:324:1-8.
172. Albini A, Fontanini G. Masiello L, Tacchetti C, Bigini D, Luzzi P. Noonan DM. Stetler-Stevenson WG: Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: Inhibition of KS like lesions by tissue inhibitor of metalloproteinase-2. AIDS 1994:8:1237-1244.
173. Benelli R, Adatia R, Ensoli B, Stetler-Stevenson WG, Santi L, Albini A: Inhibition of AIDS-Kaposi's sarcoma cell induced endothelial cell invasion by TIMP-2 and a synthetic peptide from the metalloproteina.se propeptide: Implications for an anti-angiogenic therapy. Oncol Res 1994:6:251-257.
174. Taraboletti G, Garofalo A, Belotti D. Drudis T. Borsotti P Scanziani E, Brown PD, Giavazzi R: Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloprotei nases. J Natl Cancer Inst 1985:87:293-298.
175. Schulze-Osthoff K, Risau W, Vollmer E, Sorg C: In situ detection of basic fibroblast growth factor by highly specific antibodies. Am J Pathol 1990:137:85-92.
176. Sato Y. Rifkin DB: Autocrine activities of basic fibroblast growth factor: Regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J Cell Biol 1988:107:1199-1205.
177. Mignatti P. Morimoto T, Rifkin DB: Basic fibroblast growth factor released by single, isolated cells stimulates their migration in an autocrine manner. Proc Natl Acad Sei USA 1991;88:11007-11011.
178. Mignatti P, Morimoto T, Rifkin DB: Basic fibroblast growth factor, a protein devoid of secretory signal sequence, is released by cells via a pathway independent of the endoplasmic reticulum-Goigi complex. J Cell Physiol 1992:151:81-93.
179. Bikfalvi A, Klein S, Pintucci G, Quarto N, Mignatti P, Rifkin DB: Differential modulation of cell phentotype by different molecular weight forms of basic fibroblast growth factor: Possible intracellular signaling by the high molecular weight forms. J Cell Biol 1995:129:233-243.
180. Moscatelli D, Presta M, Joseph-Silverstein J, Rifkin DB: Both normal and tumor cells produce basic fibroblast growth factor. J Cell Physiol 1988:129:273-276.
181. O Reilly MS, Holmgren L. Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of métastases by a Lewis lung carcinoma. Cell 1994:79:315-328.
182. Fidler U, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis (comment). Cell 1994;79:185-1S8.
183. Pepper MS, Vassalli JD, Montesano R, Orci L: Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. J Cell Biol 1987:105:2535-2541.
184. Pepper MS, Sappino AP, Montesano R, Orci L, Vassalli JD: Plasminogen activator inhibitor-1 is induced in migrating endothelial cells. J Cell Physiol 1992;153:129-139.
185. Pepper MS, Sappino AP, Stocklin R, Montesano R, Orci L, Vassalli JD: Up-regulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol 1993:122:673-684.
186. Fibbi G, Ziehe M, Morbidelli L, Magnelli L, Del Rosso M: Interaction of urokinase with specific receptors stimulates mobilization of bovine adrenal capillary endothelial cells. Exp Cell Res 1988:179:385-395 (published erratum in Exp Cell Res 1986;186:196).
187. Pollack R, Rifkin DB: Actin-containing cables within anchorage-dependent rat embryo cells are dissociated by plasmin and trypsin. Cell 1975;6:495-506.
188. Odekon LE, Sato Y, Rifkin DB: Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J Cell Physiol 1992;! 50: 258-263.
189. Anichini E, Fibbi G, Pucci M, Caldini R, Chevanne M, Del Rosso M: Production of second messengers following chemotactic and mitogenic urokinase-receptor interaction in human fibroblasts and mouse fibroblast transfected with human urokinase receptor. Exp Cell Res 1994:213:43848.
190. Del Rosso M, Fibbi G, Dini G, Grappone C, Pucci M, Caldini R, Magnelli L, Fimiani M, Lotti T, Panconesi E: Role of specific membrane receptors in urokinase-dependent migration of human keratinocytes. J Invest Dermatol 1990;94:310-316.
191. Del Rosso M, Anichini E, Pedersen N, Blasi F, Fibbi G, Pucci M, Ruggiero M: Urokinase-urokinase receptor interaction: Non-mitogenic signal transduction in human epidermal cells. Biochem Biophys Res Commun 1993; 190:347-352.
192. Busso N, Masur SK, Lazega D, Waxman S, Ossowski L: Induction of cell migration by prourokinase binding to its receptor: Possible mechanism for signal transduction in human epithelial cells. J Cell Biol 1994:126: 259-270.
193. Maciag T: Angiogenesis. Angiogenesis: the phenomenon; in Spaet TH (ed): Thrombosis and Haemostatis. New York, Grune & Stratton. 1984; pp 167-182.
194. Bowersox JC, Sorgente N: Chemotaxis of aortic endothelial cells in response to fibronectin. Cancer Res 1982; 42:2547-2551.
195. Alessandri G, Rajn K, Gullino PM: Mobilization of capillary endothelium in vitro induced by effectors of angiogenesis in vivo. Cancer Res 1983:43:1790-1797.
196. Viodavsky I, Korner G, Ishal-Michaeli R, Bashkin P, Bar-Shavit R, Fuks Z: Extracellular matrix-resident growth factors and enzymes: Possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev 1990:9:203-226.
197. Saksela O, Moscatelli D, Sommer A, Rifkin DB: Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 1988;107:743-751.
198. Bashkin P, Doctrow S, Klagsbrun M, Svahn CM, Folkman J, Vlodavski I: Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 1989:28:1737-1743.
199. Saksela O, Rifkin DB: Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol 1990;110:767-775.
200. DiMario J, Buffinger N, Yamada S, Strohman RC: Fibroblast growth factor in the extracellular matrix of dystrophic (mdx) mouse muscle. Science 1989:244:688-690.
201. Rogelj S, Klagsbrun M, Atzmon R, Kurokawa M, Haimovitz A, Fuks Z, Vlodavski I: Basic fibroblast growth factor is an extracellular matrix component required for supporting the proliferation of vascular endothelial cells and the differentiation of PC12 cells. J Cell Biol 1989:109:823-831.
202. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM: Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991:64:841-848.
203. Flaumenhaft R, Moscatelli D, Rifkin DB: Heparin and heparan sulfate increase the radius of diffusion and action of basic fibroblast growth factor. J Cell Biol 1990:111:1651-1659.
204. Viodavsky I, Fuks Z, Bar-Ner M, Arlav Y, Schirrmacher V: Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: Relationship to tumor cell metastasis. Cancer Res 1983;43:2704-2711.
205. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N: Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem T992;267:26031-26037.
206. Moscatelli D, Presta M, Rifkin DB: Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis and migration. Proc Natl Acad Sei USA 1986;83: 2091-2095.
207. Heimark RL, Twardzik DR, Schwanz SM: Inhibition of endothelial cell regeneration by type-beta transforming growth factor from platelets. Science 1988:233:1078-1080.
208. Muller G, Behrens J, Nussbaumer U, Bohlen P, Birchmeyer W: Inhibitory action of transforming growth factor-β on endothelial cells. Proc Natl Acad Sei USA 1987:84:5600-5604.
209. Miyazono K, Hellman U, Westedt C, Heldin CH: Latent high molecular weight complex of transforming growth factor-β,. J Biol Chem 1988:263:6407-6415.
210. Lyons RM, Keski Oja J, Moses HL: Proteolytic activation of latent transforming growth factor-β from fibroblast conditioned medium. J Cell Biol 1988;106:1659-1665.
211. Lyons RM, Gentry LE, Purchio AF, Moses HL: Mechanism of activation of latent recombinant transforming growth factor-β] by plasmin. J Cell Biol 1990:110:1361-1367.
212. Sato Y, Rifkin DB: Inhibition of endothelial cell movement by pericytes and smooth muscle cells: Activation of a latent transforming growth factor βi-like molecule by plasmin. J Cell Biol 1989:109:309-315.
213. Sato Y, Tsubol R, Lyons RM, Moses HL, Rifkin DB: Characterization of the activation of latent TGF-β by co-cultures of endothelial cells and pericytes or smooth muscle cells: A self-regulating system. J Cell Biol 1990:111:757-763.
214. Odekon LE, Blasi F, Rifkin DB: Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-beta to TGF-beta. J Cell Physio! 1994:158:39807.
215. Flaumenhaft R, Abe M. Mignatti P, Rifkin DB: Basic fibroblast growth factor-induced activation of latent transforming growth factor-β in endothelial cells: Regulation of plasminogen activator activity, i Cell Biol 1992:118:901-909.
216. Ausprunk DH, Folkman J: Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 1977:14:53-65.